← Eichor
Condition: Epithelioid Hemangioendothelioma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Epithelioid Hemangioendothelioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Phase N/A · 22 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06408441A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Phase N/A · 40 location(s) · Federation Francophone de Cancerologie Digestive · NCT06541652Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the
NA · 20 location(s) · Institut Claudius Regaud · NCT03967834A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Phase 1 · 1 location(s) · BridGene Biosciences Inc. · NCT06452160NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Phase 2 · 6 location(s) · Sarcoma Alliance for Research through Collaboration · NCT07104331Epithelioid Haemangioendothelioma Observational Study
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06680401
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.